CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: miR-181a-transduced and control CML CD34+ cells were subjected to IM treatment, and the data showed that miR-181a enhanced the IM response of CML CD34+ cells (Fig. 2C).